Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• Enthesitis is a primary characteristic of spondyloarthritis (SpA).
• Current treatments face challenges in managing enthesitis inflammation and new bone formation (NBF).

Purpose of the Study:

• To review the immunopathogenesis of enthesitis in spondyloarthritis.
• To highlight recent findings on immune cell involvement and cytokine signaling in enthesitis.

Main Methods:

• Review of current scientific literature on enthesitis and spondyloarthritis immunopathogenesis.
• Analysis of studies focusing on immune cell populations (e.g., γδ T cells, ILC3s, myeloid cells) and cytokines (e.g., IL-17, IL-23, IL-22, GM-CSF).

Main Results:

• Specific immune cells like γδ T cells and group 3 innate lymphoid cells (ILC3) play significant roles.
• Interleukin-17 (IL-17) production independent of IL-23 has been observed in human spinal entheses.
• Key cytokines including IL-22 and granulocyte-macrophage colony-stimulating factor (GM-CSF) are pivotal in entheseal inflammation and NBF.

Conclusions:

• The immunopathogenesis of enthesitis is complex, involving diverse immune cells and signaling pathways.
• Recent advances provide a foundation for identifying novel therapeutic targets for SpA-related enthesitis.
• Further research into these immune mechanisms is warranted to improve treatment strategies.